Based on a phase Ib clinical trial of patients with unresectable HCC, the PD-L1 inhibitor atezolizumab plus the VEGF inhibitor bevacizumab significantly suppressed HCC progression and improved PFS compared to atezolizumab monotherapy (20). This evidence concerns the gene VEGFA and hepatocellular carcinoma.